First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
Executive Summary
The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.